| Programme | Time (SGT) |
|---|---|
| Chronic Hepatitis B And D | |
| Chairs | |
| Opening comments and introduction Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
|
| CHB Grey zone: clinical significance Adj Assoc. Prof. Daniel Huang, National University Health System, Singapore View Bio |
|
| Landscape of Hepatitis B cure in 2026 Prof. Man Fung Yuen, Hong Kong University, Hong Kong View Bio |
|
| GSK Symposium Integrating qHBsAg Testing into Routine Clinical Practice: Optimizing the Journey Towards Functional Cure in CHB Speaker: Prof. Grace Wong, Chinese University of Hong Kong, Hong Kong,View Bio Moderator: Dr. Tan Poh Seng, PS Tan Digestive & Liver Centre, Singapore, View Bio |
|
| Q&A | 7.50pm to 8.15pm |
| Break | 8.15 pm to 8.30 pm |
| Gene therapy for CHB Prof. Ed Gane, University of Auckland, New Zealand View Bio |
|
| Immune suppression and HBV Prof. Teerha Piratvisuth, Prince of Songkla University, Thailand View Bio |
|
| Management of severe hepatitis B Flares Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
|
| Delta Hepatitis Update Prof. Pietro Lampertico, University of Milan, Italy View Bio |
|
| Q&A | 9.50 pm to 10.15 pm |
| Close | 10.15pm |
SHC 2026 Scientific Programme
August, 2026
31
September, 2026
1
| Programme | Time (SGT) |
|---|---|
| MASLD & MASH | |
| Opening comments and Introduction Adj. Prof. Mark Muthiah, National University Health System, Singapore View Bio |
|
| Phenotype-genotype interactions in MASLD: A south east asian perspective Prof. Chan Wah Kheong, University of Malaya, Malaysia View Bio |
|
| Screening for MASLD in the community: are our protocols ready? Prof. Neeraj Bhala View Bio |
|
| Q&A | 07.35pm to 08.00pm |
| Break | 08.00pm to 08.20pm |
| Debate: MASLD and MASH has lost its relevance – we should only be screening for fibrosis (con) Prof. Vincent Wong, Chinese University of Hong Kong, Hong Kong View Bio |
|
| Debate: MASLD and MASH has lost its relevance – we should only be screening for fibrosis (pro) Adj. Prof. Mark Muthiah View Bio |
|
| Q&A | 09.00pm to 09.20pm |
| A practical approach to treatment of MASH (pre-recorded) Prof. Jacob George, University of Sydney, Australia View Bio |
|
| Extra-hepatic caridometabolic consequences in MASLD: when to screen Prof. M Shadab Siddiqui, University of Virginia, USA View Bio |
|
| Q&A | 10.10pm to 10.30pm |
September, 2026
2
| Programme | Time (SGT) |
|---|---|
| Hepatocellular carcinoma (HCC) | |
| Opening comments and Introduction Adj. Assoc. Prof. Daniel Huang, National University Health System, Singapore View Bio |
|
| Updates in systemic therapy for HCC Prof. Arndt Vogel, Hannover Medical School, Germany View Bio |
|
| Conversion therapy for initially unresectable HCC Prof. Masatoshi Kudo, Kindai University, Japan View Bio |
|
| HCC risk stratification Prof. Luca Valenti, University of Milan, Italy View Bio |
|
| Q&A | 08.00 pm to 08.20 pm |
| Break | 8.20pm to 8.30pm |
| Loco-regional therapy in intermediate HCC Prof. Pierce Chow, Duke-NUS Graduate School of Medicine, Singapore View Bio |
|
| Prevention and surveillance for hepatocellular carcinoma in chronic hepatitis B Prof. Grace Wong, Chinese University of Hong Kong, Hong Kong View Bio |
|
| MASLD-related HCC: risk prediction, surveillance, and prevention Prof. Leon Adams, University of Western Australia, AustraliaView Bio |
|
| Q&A | 09.45 pm to 10.00 pm |
September, 2026
3
| Programme | Time (SGT) |
|---|---|
| Advanced Liver Diseases | |
| Opening comments and Introduction – Adj A/Prof Lee Guan Huei National University Health System, Singapore View Bio |
|
| “Alcohol-related liver disease and transplantation in the Asia-Pacific: practical lessons from an Australian national transplant programme” Dr. Anastasia Volovet, Sydney Local Health District, Australia View Bio |
|
| “MetALD in Singapore: building a clinic pathway—non-invasive risk stratification, multidisciplinary care, and when to escalate” Dr. Benjamin Nah, National University Hospital, Singapore View Bio |
|
| “Treating Alcohol Use Disorder as core liver care: pharmacotherapy,relapse prevention, and shared-care models between hepatology and addiction services” Dr. Charles Mak, IMH/NAMS, Singapore View Bio |
|
| Q & A Session | 08.00 pm to 08.20 pm |
| Break | 08.20 pm to 08.30 pm |
| “ALD and liver transplantation: from early LT for severe AAH to long-term outcomes—what systems must change” Prof. Sumeet K. Asrani Baylor Simmons Transplant Institute Dallas, Texas, USA View Bio |
|
| Update on the diagnosis and treatment of MetALD Prof. Maja Thiele, University of Southern Denmark View Bio |
|
| Q & A Session | 09.20 pm to 09.35 pm |
| Close | 09.35 pm |